Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.